Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsing-remitting Multiple Sclerosis (RRMS)”

180 trials

Showing 20 of 180 results

Not applicableStudy completedNCT00818038
What this trial is testing

A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 30
Large-scale testing (Phase 3)Looking for participantsNCT06700343
What this trial is testing

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Who this might be right for
Relapsing-remitting Multiple Sclerosis (RRMS)
Amgen 444
Large-scale testing (Phase 3)Study completedNCT01167426
What this trial is testing

Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients

Who this might be right for
Multiple Sclerosis
Teva Neuroscience, Inc. 148
Large-scale testing (Phase 3)Study completedNCT02637856
What this trial is testing

Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Genentech, Inc. 608
Post-approval studies (Phase 4)Active Not RecruitingNCT03535298
What this trial is testing

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
The Cleveland Clinic 800
Not applicableStudy completedNCT02277964
What this trial is testing

Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod

Who this might be right for
Relapsing Remitting Multiple Sclerosis
University Hospital, Basel, Switzerland 25
Post-approval studies (Phase 4)Study completedNCT01705236
What this trial is testing

A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®

Who this might be right for
Relapsing Remitting Multiple Sclerosis RRMS
Novartis Pharmaceuticals 87
Large-scale testing (Phase 3)Active Not RecruitingNCT03477500
What this trial is testing

Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)

Who this might be right for
Multiple Sclerosis
Haukeland University Hospital 100
Large-scale testing (Phase 3)Study completedNCT00428584
What this trial is testing

RNF and Betaseron® Tolerability Study

Who this might be right for
Relapsing Remitting Multiple Sclerosis (RRMS)
EMD Serono 129
Large-scale testing (Phase 3)Study completedNCT03689972
What this trial is testing

Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Biogen 585
Not applicableStudy completedNCT02588053
What this trial is testing

Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?

Who this might be right for
Multiple Sclerosis
University of Colorado, Denver 85
Testing effectiveness (Phase 2)Ended earlyNCT01037907
What this trial is testing

Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Boston Scientific Corporation 173
Not applicableWithdrawnNCT05172466
What this trial is testing

Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab

Who this might be right for
Relapsing-remitting Multiple Sclerosis (RRMS)
Icahn School of Medicine at Mount Sinai
Testing effectiveness (Phase 2)Study completedNCT01156311
What this trial is testing

BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple SclerosisMultiple Sclerosis
Biogen 108
Large-scale testing (Phase 3)Study completedNCT01838668
What this trial is testing

An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing-Remitting Multiple SclerosisMultiple Sclerosis
Biogen 225
Early research (Phase 1)Active Not RecruitingNCT06430671
What this trial is testing

Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis (RRMS)
Cellerys AG 11
Large-scale testing (Phase 3)Ended earlyNCT03085810
What this trial is testing

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Hoffmann-La Roche 1,225
Large-scale testing (Phase 3)Study completedNCT00213135
What this trial is testing

A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
EMD Serono 1,326
Large-scale testing (Phase 3)Study completedNCT02525874
What this trial is testing

Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis
Biogen 218
Very early researchStudy completedNCT00618527
What this trial is testing

Combination Therapy Using Cellcept and Rebif in RRMS

Who this might be right for
Multiple Sclerosis
Aaron Boster 31
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation